Table 4. Without using the perturbation analysis this table (thresholded at SetS≥5) lists compounds with significant connections to the cervical cancer gene signature.
| REF | SetS | GeneLen | SetNo |
| trichostatin A | 182 | 100 | −0.1124 |
| fluphenazine | 18 | 100 | −0.0953 |
| 15-delta prostaglandin J2 | 15 | 100 | −0.1109 |
| resveratrol | 9 | 100 | −0.0904 |
| 0179445-0000 | 8 | 100 | −0.0927 |
| gossypol | 6 | 100 | −0.1532 |
| pyrvinium | 6 | 100 | −0.1452 |
| rofecoxib | 6 | 100 | −0.0870 |
| clotrimazole | 5 | 100 | −0.1205 |
| halcinonide | 5 | 100 | −0.1188 |
| trimethoprim | 5 | 100 | 0.0812 |
| sulfamethoxazole | 5 | 100 | 0.0853 |
| riluzole | 5 | 100 | 0.1007 |
| naphazoline | 5 | 100 | 0.0888 |
| iproniazid | 5 | 100 | 0.1117 |
| hydrochlorothiazide | 5 | 100 | 0.0898 |
| guanadrel | 5 | 100 | 0.1103 |
| diphemanil metilsulfate | 5 | 100 | 0.1180 |
| prilocaine | 6 | 100 | 0.0582 |
| paclitaxel | 6 | 100 | 0.0881 |
| genistein | 17 | 100 | 0.0760 |
REF is the (drug) name for the reference set; SetS is the setsize; GeneLen is the length of gene signature; SetNo is the setscore.